key: cord-0833366-tcwlfra7
authors: Romero Olmedo, A. J.; Schulz, A. R.; Hochstaetter, S.; Das Gupta, D.; Hirseland, H.; Staudenraus, D.; Camara, B.; Volland, K.; Hefter, V.; Sapre, S.; Kraehling, V.; Mueller-Kraeuter, H.; Mei, H.; Keller, C.; Lohoff, M.
title: Differential durability of humoral and T cell immunity after two and three BNT162b2 vaccinations in adults aged >80 years
date: 2022-02-15
journal: nan
DOI: 10.1101/2022.02.10.22270733
sha: 0b7238b2503a06371a23edc8d6c7bc64961080c1
doc_id: 833366
cord_uid: tcwlfra7

A third mRNA-based "booster" vaccination is the favored strategy to maintain protection against SARS-CoV-2 infection. Yet, significant waning of specific immunity within six months after 2nd vaccination, along with higher incidence of breakthrough infections associated with the time elapsed since 2nd vaccination raises concerns regarding the durability of immunity also after 3rd vaccination. We address the currently debated consequence of a third vaccination against SARS-CoV-2 for generating durable immunity especially in older adults. Specifically, we assessed virus-specific serum antibody and single cell blood T cell responses after vaccination with the mRNA vaccine BNT162b2 in more than 50 individuals older than 80 years. All old adults demonstrate a strong humoral response to 3rd vaccination which is higher and wanes slower than the response to 2nd vaccination, indicative of enhanced humoral immunity. In contrast, their respective T cell response reaches only the level obtained after 2nd vaccination, with similar waning over time and no enhancement of IFN{gamma} production per cell. Because BNT162b2-mediated protection from the Omicron variant relies more on T cells than antibodies, our findings raise concern on the durability of protection from the Omicron variant by BNT162b2 in a population at risk.

A third mRNA-based "booster" vaccination is the currently favored strategy to maintain protection against SARS-CoV-2 infection. Yet, significant waning of specific immunity within six months after 2 nd vaccination 1 , along with higher incidence of breakthrough infections associated with the time elapsed since 2 nd vaccination 2, 3 raises concerns regarding the durability of immunity also after 3 rd vaccination.

We compared the specific humoral and cellular response ( Fig.1A -C) after 3 rd vs. 2 nd vaccination with BNT162b2 in a cohort of adults aged >80 years (sTable1,2 4 ) at risk for severe COVID-19 and immune senescence. Our data demonstrate the induction of marginally higher spike S1-specific blood IgG concentrations two weeks after 3 rd than after 2 nd vaccination (sFig.1A, Fig.1D ). By contrast, functionally relevant RBDspecific IgG (Fig.1B) and SARS-CoV-2-neutralizing antibody (sFig.1B) titers were substantially increased (Fig.1D ) after 3 rd compared to 2 nd vaccination, reflecting enhanced antibody production and/or affinity maturation.

In contrast, spike-specific CD4 T cell frequencies reached similar levels after 2 nd and 3 rd vaccination (Fig.1C,D) . After the respective acute response, frequencies returned to approximately pre-vaccination levels with similar rates of decline after 2 nd and 3 rd vaccination (week 24 and 40, respectively, Fig.1C ,E, sFig.2). Quantified cytoplasmic expression of the effector cytokine IFNindicated functional enhancement of spikespecific T cells upon 2 nd but not further upon 3 rd vaccination, while more cytoplasmic IFNwas found in spike-specific CD4 T cells from senior adults recovered from COVID-19 (Fig.1F) . Thus, even a third BNT162b2 dose failed to induce durably enhanced quantities of spike-specific T cells and a functional quality reached after natural infection.

Concentrations of S1-and RBD-specific IgG also declined from the acute responses at week 5 and week 26, but clearly at a lower rate after 3 rd (week 40) compared to 2 nd (week 24) vaccination ( Fig.1B ,E, sFig.1A, sFig.2), yielding persistently enhanced IgG quantity and/or quality after the 3 rd vaccination. We conclude that a third vaccination against SARS-CoV-2 in older adults, while establishing immunity in . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 primary non-responders 4 , induces a durably escalated humoral response in the bulk of vaccinees for at least three months, indicating longer lasting humoral immunity.

However, BNT162b2-induced immune reactivity against the emerging Omicron variant is predominantly T cell-mediated 5, 6 . Thus, the apparent inability of older adults to develop and maintain high levels of fully matured SARS-CoV-2-reactive T cells after 3 rd vaccination is of concern. Additional immunizations with vaccines designed to target "variants of concern" and improve T cell reactivity will be required to satisfactorily protect senior adults from COVID-19. respectively. Log2 of the fold change in peak response values for spike (S1 subunit)-and RBDspecific IgG (n = 33), neutralizating antibody titers (n = 15), and spike-specific T cell frequencies (n = 32) in participants after 2 nd and 3 rd vaccination (D). Slope of the declining peak response (sFig.2) after 2 nd (1 st contraction) or 3 rd (2 nd contraction) vaccination, calculated for S1-and RBD-specific IgG titers is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; sFigure 1. Increased antibody response in >80 year-old donors after receiving a third dose of the BNT162b2 vaccine.

SARS-CoV-2 spike (S1-sbunit)-specific serum IgG levels (A) and serum titers of 100% virus neutralization for SARS-CoV-2 wild type B.1 (VNT 100) (B) were analyzed in donors aged >80 years at the indicated time points after primary vaccination with BNT162b2 (see Figure 1A for study overview). Each symbol is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.10.22270733 doi: medRxiv preprint sFigure 2. Contraction of SARS-CoV-2 specific CD4 T cell and humoral immunity after second and third "booster" vaccination with BNT162b2.

Normalized slopes of serum SARS-CoV-2 RBD-specific IgG, S1-specific IgG, and circulating SARS-CoV-2 spike-specific CD4 T cells, after the second dose (first contraction, grey dots) and after the third dose (second contraction, green dots) of BNT162b2. Weeks indicated on the x axis are weeks after respective peak responses. Fitted linear regression lines are shown as dashed lines. Slopes were calculated by linear regression from log-transformed data. Data for each donor and each contraction was normalized to a value of 1 at week 5 (first contraction) and

week 26 (second contraction). Slopes were calculated from 14 donors (RBD-and S1-specific IgG serum responses) and 12 donors (spike-specific CD4 T cell responses. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Up to six blood samples were obtained from participants aged >80 years by venipuncture as shown in Fig. 1A . Samples were collected before first (week 0, W0), and three weeks (W3, right before 2 nd vaccination), five weeks (W5) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.10.22270733 doi: medRxiv preprint streptomycin, and 10% human AB serum (all Sigma, St. Louis, MO) at 5 x 10 6 cells / mL.

Antigen-reactive T cell responses were analyzed using a protocol based on previous work 1 . 500 µL media containing 5 x 10 6 PBMC were transferred into 12 mL round-bottom tubes (Greiner Bio-One GmbH, Frickenhausen, Germany) and stimulated with either SARS-CoV-2 spike protein peptide mix (wildtype, Miltenyi is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 permeabilization buffer supplemented with antibodies targeting CD40L ( Antigen-reactive CD4 T cells (ART) were defined as CD40L+ IFN+ expressing cells after spike peptide stimulation, and their frequencies were determined among total CD4 T cells.

T cells from unstimulated control samples were subtracted from ART frequencies for each individual donor. Whenever this difference was equal to or below 0%, frequencies were set to 0.0001%, a value exceeded by all measurements in which ART were detectable, in order to allow the display of data on a logarithmic scale in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101/2022.02.10.22270733 doi: medRxiv preprint a 5 % CO2 atmosphere, and cytopathic effects were evaluated at day 4 post infection. Neutralization was defined as the absence of cytopathic effects in the serum dilutions. The reciprocal neutralization titer was calculated from the highest serum dilution without cytopathic effects as a geometric mean based on three replicates. The lower detection limit of the assay is 8 (reciprocal titer) for week 24 sera and 16 for week 26 sera, corresponding to the first dilution of the respective serum. Two positive controls were used as inter-assay neutralization standards and quality control for each test. Neutralization assays were performed in the BSL-4 laboratory of the Institute of Virology at Philipps University Marburg, Germany.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted February 15, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Statistical analysis details Prism version 9 (GraphPad software, San Diego, CA) was used to display data, and perform descriptive statistics and significance testing. To determine differences between cohorts in Fig. 1F (vaccinated group W26 vs recovered group), a two-tailed Mann-Whitney test was applied to calculate the P value. For assessing donor-specific responses over time, the two-tailed Wilcoxon matched-pairs signedrank test was used. Slopes reflecting immune contractions were calculated by linear regression from log-transformed data. Data for each donor and each contraction was normalized to 1 for week 5 (first contraction) and week 26 (second contraction).

Donors selected to evaluate contractions (slopes) were those who participated also in W40. Slopes were calculated from 14 donors (RBD and spike IgG serum responses) and 12 donors (spike-specific CD4 T cell responses).

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Ancestral SARS-CoV-2-specific T cells crossrecognize the Omicron variant

Sera exceeding the detection range of the assay (40,000 AU /mL) were automatically pre-diluted 1:2 by the device and measured again

Serum IgG directed against the S1 subunit of the SARS-CoV-2 spike protein was quantified in BAU / mL using the Anti-SARS-CoV-2-QuantiVac ELISA

Primary data obtained in relative units per mL were converted into binding antibody units (BAU) / mL by multiplication with the factor 3.2, according to the manufacturer's instructions. Results in BAU / mL are calibrated against the "First WHO International Standard for anti-SARS-CoV-2 immunoglobulin (NIBSC code: 20/136)". The lower cutoff for this assay is at 35.2 BAU / mL

SARS-CoV-2 neutralization tests (VNT-100)

One hundred plaque-forming units (PFU) of SARS-CoV-2 were added in the same volume to the serum dilutions. The German SARS-CoV-2 virus isolate BavPat1/2020 (European Virus Archive Global #026 V-03883, Genbank: MZ558051.1) was used. The sequence of the viruses was confirmed. Following incubation at 37 °C for 1 h

RRID: CVCL_0574) were added. Plates were then incubated at 37 °C in 1

Low Thymic Activity and Dendritic Cell Numbers Are Associated with the Immune Response to Primary Viral Infection in Elderly Humans

flowAI: automatic and interactive anomaly discerning tools for flow cytometry data

The authors wish to thank all participating donors and especially the vaccination center in Germany, and its Chief Manager K. Oerder for excellent support throughout this study.